Rigel Pharmaceuticals RIGL Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $40.64M-28.4% | $56.75M+73.1% | $32.79M+34.0% | $24.46M+29.5% | ||
| $114.38M+456% | $20.58M-14.8% | $24.15M-28.4% | $33.75M-68.2% | ||
| $51.76M+24.4% | $41.62M+36.2% | $30.55M-24.2% | $40.32M+161% | ||
| $11.51M+91.7% | $6M+8.7% | $5.52M-39.4% | $9.12M+37.8% | ||
| $240.17M+77.8% | $135.1M+36.1% | $99.27M-14.4% | $115.9M-25.0% | ||
| $24.75M-8.7% | $27.1M+95.3% | $13.88M-7.2% | $14.95M— | ||
| $24.75M-8.7% | $27.1M— | —— | —— | ||
| $513.59M+213% | $163.98M+39.9% | $117.23M-12.7% | $134.28M-19.8% | ||
| $7.19M+115% | $3.34M-53.2% | $7.14M-68.3% | $22.51M+493% | ||
| $30M— | —— | —— | —— | ||
| $99.24M+56.8% | $63.3M+18.8% | $53.27M-18.3% | $65.21M+2.6% | ||
| $52.5M— | —— | —— | —— | ||
| $122.11M-24.0% | $160.69M+10.2% | $145.87M-1.4% | $147.9M+8.0% | ||
| $18K-100.0% | $400M+2,352,841% | $17K-90.2% | $174K+1.2% | ||
| -$1.02B+26.4% | -$1.39B+1.2% | -$1.41B-1.8% | -$1.38B-4.4% | ||
| $391.48M+11,806% | $3.29M+111% | -$28.64M-110% | -$13.62M-145% | ||
| $513.59M+213% | $163.98M+39.9% | $117.23M-12.7% | $134.28M-19.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rigel Pharmaceuticals's total assets?
- Rigel Pharmaceuticals (RIGL) holds $504.6M in total assets, up 186.8% year over year.
- How much debt does Rigel Pharmaceuticals have?
- Rigel Pharmaceuticals carries $68.4M in total debt against $399.9M of shareholders' equity, a debt-to-equity ratio of 0.17.
- How much cash does Rigel Pharmaceuticals have?
- Rigel Pharmaceuticals holds $24.5M in cash and equivalents.
- Can Rigel Pharmaceuticals cover its short-term obligations?
- Its current ratio is 2.62 — current assets exceed current liabilities.
- Where does Rigel Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
